1. Introduction {#sec1}
===============

The health status of Canadians has improved during the 21st century. Life expectancy at birth increased from 79.24 years in 2000 to 82.14 years in 2015. Also, the age-standardized rate of potential years of life lost before age 75[1](#fn1){ref-type="fn"} per 100,000 population declined from 4214 during 1999--2003 to 3601 during 2009--2013---a 15% decline ([@bib32]).

Some researchers have argued that biomedical innovation has been the principal cause of recent improvements in health. [@bib11] said that "since World War II ... biomedical innovations (new drugs, devices, and procedures) have been the primary source of increases in longevity," although he did not provide evidence to support this claim. [@bib7] performed a survey of a large and diverse literature on the determinants of mortality, and "tentatively identif\[ied\] the application of scientific advance and technical progress (some of which is induced by income and facilitated by education) as the ultimate determinant of health." They concluded that "knowledge, science, and technology are the keys to any coherent explanation" of mortality. Other research has shown that most technological progress is "embodied": to benefit from technological progress, people must use new products and services.[2](#fn2){ref-type="fn"}

Most scholars agree with [@bib16], pp. 89--90) statement that "technological progress is driven by research and development (R&D) in the advanced world." In 1997, the medical substances and devices sector was the most R&D-intensive[3](#fn3){ref-type="fn"} major industrial sector in the U.S.: almost twice as R&D-intensive as the next-highest sector (information and electronics), and three times as R&D-intensive as the average for all major sectors. ([@bib26]). According to [@bib10], in 2008, 88% of privately-funded U.S. biomedical research expenditure was funded by pharmaceutical and biotechnology firms; the remaining 11% was funded by medical device firms.

The purpose of this study is to assess econometrically the role that pharmaceutical innovation---the introduction and use of new drugs---has played in reducing the burden of disease in Canada. During the period 1980--2016, drugs with 1404 new ATC codes were launched in Canada: about 39 new ATC codes per year, on average.[4](#fn4){ref-type="fn"} For reasons discussed below, there is likely to be a substantial lag between the launch of a new drug and its maximum impact on the burden of disease, so we will allow for considerable lags in the relationship between new drug launches and the burden of disease.

The analysis will be performed using a difference-in-differences (or two-way fixed effects) research design: we will investigate whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. This design controls for the effects of general economic and societal factors (e.g. income, education, and behavioural risk factors[5](#fn5){ref-type="fn"}), to the extent that those effects are similar across diseases, e.g. smoking increases mortality from respiratory and cardiovascular disease as well as lung cancer, and education reduces mortality from all diseases.

The number of new drug launches varied considerably across diseases.[6](#fn6){ref-type="fn"} [Fig. 1](#fig1){ref-type="fig"} shows the number of chemical substances used to treat 5 diseases that had ever been launched in Canada during the period 1980--2016. These five diseases were selected because an identical number of---six--- chemical substances had been launched for each disease by the year 1980. During the next 36 years, 14 new drugs for treating ovary cancer were launched; between 5 and 7 new drugs for treating gonorrhea, bladder cancer, and bipolar disorder were launched; only one new drug for treating gout was launched.Fig. 1Number of (WHO ATC5) chemical substances ever launched, 5 diseases, Canada, 1980--2016.Source: Author\'s calculations based on data contained in Health Canada Drug Product Database and Thériaque database.Fig. 1

The primary measure of disease burden we will analyze is the number of disability-adjusted life-years (DALYs) lost, as defined and measured by the [@bib36]. The DALY is a summary measure that combines time lost through premature death and time lived in states of less than optimal health, loosely referred to as "disability". The DALY is a generalization of the well-known potential Years of Life Lost measure (YLLs) to include lost good health. One DALY can be thought of as one lost year of 'healthy' life, and the measured disease burden is the gap between a population\'s health status and that of a normative reference population. DALYs for a specific cause are calculated as the sum of the YLLs from that cause and the years of healthy life lost due to disability (YLDs) for people living in states of less than good health resulting from the specific cause. The YLLs for a cause are essentially calculated as the number of cause-specific deaths multiplied by a loss function specifying the years lost for deaths as a function of the age at which death occurs.[7](#fn7){ref-type="fn"}

[Table 1](#tbl1){ref-type="table"} shows data on the number of DALYs lost (due to all causes) and population, by age group, in Canada in 2000 and 2016. Almost 9 million DALYs were lost in 2016. As shown in row 8, the crude DALY rate (DALYs lost per 100 population) declined by just 2% between 2000 and 2016. However, the DALY rate generally increases sharply with age (e.g., in 2016, the rate among people age 70 and over was about 3 times as high as the rate among people age 50--59), and the Canadian population is aging: the fraction of the population that was age 60 and over increased from 17% in 2000 to 23% in 2016. The age-standardized DALY rate declined by 14% between 2000 and 2016, and the rates among people age 60 and over declined by 20--22%. We will analyze the impact of new drug launches on the age-standardized DALY rate and on its two components: the age-standardized YLL and YLD rates. We will also analyze the impact of new drug launches on the number of hospital discharges and on the average length of hospital stays.Table 1DALYs lost and population by age group, Canada, 2000 and 2016.Table 1row20002016age group (years)DALYs lost (000s)Population (000s)DALYs lost per 100 populationDALYs lost (000s)Population (000s)DALYs lost per 100 population% decline in DALYs lost per 100 population, 2000--201610--4227179312.7213192911.113%25--1419440964.716138674.212%315--29744624811.9798703811.35%430--491678986717.01512971315.68%550--591079360929.91451542826.711%660--691214240450.51688428539.422%770+2574271894.73071403176.220%8Total77113073525.188963629124.52%  % of total% of total90--43%6%2%5%105--143%13%2%11%1115--2910%20%9%19%1230--4922%32%17%27%1350--5914%12%16%15%1460--6916%8%19%12%1570+33%9%35%11%16Total100%100%100%100%17Age-standardized rate^1^25.121.514%[^1]Source: World Health Organization, Disease burden and mortality estimates, <http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html>

In the next section, we will describe the econometric model that we will use to assess the role that pharmaceutical innovation has played in reducing the burden of disease in Canada during the period 2000--2016. The data sources used to estimate this model are discussed on Section III. Empirical results are presented in Section IV. Some implications of the estimates are discussed in Section V. Section VI provides a summary.

2. Methods {#sec2}
==========

To assess the impact that pharmaceutical innovation had on the burden of disease, we will estimate models based on the following 2-way fixed effects equation[8](#fn8){ref-type="fn"}:where Y~dt~ is one of the following variables:DALY~dt~ = the age-standardized rate of DALYs lost due to disease d in year t (t = 2000, 2016)YLL~dt~ = the age-standardized rate of years of life lost due to disease d in year tYLD~dt~ = the age-standardized rate of years of healthy life lost due to disability due to disease d in year tand.CUM_DRUG~d,t-k~ = ∑~m~ IND~md~ LAUNCHED~m,t-k~ = the number of chemical substances to treat disease d that had been launched in Canada by the end of year t-k (k = 0, 1, 2, ...,20)IND~md~ = 1 if chemical substance m is used to treat (indicated for) disease d [9](#fn9){ref-type="fn"}IND~md~ = 0 if chemical substance m is not used to treat (indicated for) disease dLAUNCHED~m,t-k~ = 1 if chemical substance m had been launched in Canada by the end of year t-k = 0 if chemical substance m had not been launched in Canada by the end of year t-kα~d~ = a fixed effect for disease dδ~t~ = a fixed effect for year t

Eq. [(1)](#fd1){ref-type="disp-formula"} may be considered a health production function ([@bib19]), and the number of chemical substances ever launched may be considered a measure of the stock of pharmaceutical "ideas." [@bib17] argued that "long-run growth is driven by the discovery of new ideas throughout the world."[10](#fn10){ref-type="fn"} The log-log specification of eq. [(1)](#fd1){ref-type="disp-formula"} incorporates the assumption of diminishing marginal productivity of chemical substance launches: each additional chemical substance launch for a medical condition results in a diminishing absolute reduction in disease burden. If the cost of chemical substance launches for different diseases were equal, it would be socially optimal to equalize the absolute reductions in disease burden across diseases. A small percentage reduction in the burden of a high-burden disease would be as valuable as a large percentage reduction in the burden of a low-burden disease.

Estimates based on eq. [(1)](#fd1){ref-type="disp-formula"} will provide evidence about the impact of the launch of drugs for a disease on the burden of that disease, but they will not capture possible spillover effects of the drugs on the burden of *other* diseases. These spillovers may be either positive or negative. For example, the launch of cardiovascular drugs could reduce mortality from cardiovascular disease, but increase mortality from the "competing risk" of cancer. On the other hand, the launch of drugs for mental disorders could reduce mortality from other medical conditions. [@bib29] argued that "mental disorders increase risk for communicable and non-communicable diseases, and contribute to unintentional and intentional injury. Conversely, many health conditions increase the risk for mental disorder, and comorbidity complicates help-seeking, diagnosis, and treatment, and influences prognosis."

Due to data limitations, ln(CUM_DRUG~d,t-k~) is the only disease-specific, time-varying regressor in eq. [(1)](#fd1){ref-type="disp-formula"}. If the data were available, we would like to include other regressors in eq. [(1)](#fd1){ref-type="disp-formula"}, including (1) disease incidence, and (2) the number of non-pharmaceutical medical innovations (e.g. medical device innovations) that had been launched in Canada. However, there is good reason to believe that failure to control for those variables is unlikely to result in overestimation of the magnitude of β~k~; exclusion of those variables may even result in *underestimation* of the magnitude of β~k~. Higher disease incidence is likely to result in both higher disease burden and a larger number of chemical substance launches:Image 2

Previous studies have shown that both innovation (the number of drugs developed) and diffusion (the number of drugs launched in a country) depend on *market size*. [@bib1] found "economically significant and relatively robust effects of market size on innovation." [@bib8] found that "countries with lower expected prices or *smaller expected market size experience longer delays in new drug access*, controlling for per capita income and other country and firm characteristics" (emphasis added).

Although incidence data are not available for most diseases, annual incidence data for the period 1992--2010 are available for 31 cancer sites (breast, lung, etc.). As expected, there is a significant *positive* correlation across cancer sites between ln(CASES~st~) (where CASES~st~ = the number of patients diagnosed with cancer at cancer site s in year t) and ln(CUM_DRUG~st~) (where CUM_DRUG~st~ = the number of chemical substances to treat cancer at site s that had ever been launched by the end of year t). But estimates of the equation ln(CUM_DRUG~st~) = π ln(CASES~st~) + α~s~ + δ~st~ + ε~st~ indicate that the *growth rate* of CUM_DRUG is uncorrelated across cancer sites with the *growth rate* of incidence. This suggests that estimates of β~k~ in eq. [(1)](#fd1){ref-type="disp-formula"} are unlikely to be biased by the omission of incidence in that equation.

Failure to control for non-pharmaceutical medical innovation (e.g. innovation in diagnostic imaging, surgical procedures, and medical devices) is also unlikely to bias estimates of the effect of pharmaceutical innovation on the burden of disease, for two reasons. First, as noted earlier, 88% of privately-funded U.S. funding for biomedical research came from pharmaceutical and biotechnology firms ([@bib10]).[11](#fn11){ref-type="fn"} Second, previous research based on U.S. data ([@bib20]; [@bib21]) indicated that non-pharmaceutical medical innovation is not positively correlated across diseases with pharmaceutical innovation.

The dependent variable of eq. [(1)](#fd1){ref-type="disp-formula"} is the log of the *level* of disease burden in year t. We will use data for two years: 2000 and 2016. Substituting those two values of t into eq. [(1)](#fd1){ref-type="disp-formula"} yields:

Subtracting eq. [(2)](#fd2){ref-type="disp-formula"} from eq. [(3)](#fd3){ref-type="disp-formula"} yields:whereΔln(Y~d~) = ln(Y~d,2016~/Y~d,2000~)Δln(CUM_DRUG_k~d~) = ln(CUM_DRUG~d,2016-k~/CUM_DRUG~d,2000-k~)δ' = (δ~2016~ - δ~2000~)ε~d~' = (ε~d,2016~ - ε~d,2000~)

Eq. [(4)](#fd4){ref-type="disp-formula"} is a simple regression of the 2000--2016 *growth* in the burden of disease d on the growth in the number of drugs that were used to treat disease d that had ever been launched k years earlier.[12](#fn12){ref-type="fn"} To address the issue of heteroskedasticity,[13](#fn13){ref-type="fn"} eq. [(4)](#fd4){ref-type="disp-formula"} will be estimated by weighted least squares, weighting by (Y~d,2000~ + Y~d,2016~)/2.

The mean (across all medical conditions) 2000--2016 log change in disease burden from drugs launched k years earlier is Δ~k~ = β~k~ \* mean (Δln(CUM_DRUG_k~d~)). The (absolute) reduction in 2016 disease burden from drugs launched between 2000 -- k and 2016 -- k is (∑~d~ Y~d,2016~) \* (1 - (1/exp(Δ~k~))).

We will estimate 63 (= 3 \* 21) versions of eq. [(4)](#fd4){ref-type="disp-formula"}: one for each of the three measures of disease burden (DALY, YLL, and YLD) for 21 different lag values (k = 0, 1, ..., 20). There is likely to be a substantial lag between the launch of a new drug and its maximum impact on the burden of disease. Utilization of recently-launched drugs tends to be much lower than utilization of drugs launched many years earlier. Evidence about the shape of the drug-age (number of years since launch) drug-utilization profile can be obtained by estimating the following equation:whereN_SU~mn~ = the number of standard units of molecule m sold in Canada n years after it was first launched (n = 0, 1, ..., 20)ρ~m~ = a fixed effect for molecule mπ~n~ = a fixed effect for age n

The expression exp(π~n~ - π~14~) is a "relative utilization index": it is the mean ratio of the quantity of a drug sold n years after it was launched to the quantity of the same drug sold 14 years after it was launched. We estimated eq. [(5)](#fd5){ref-type="disp-formula"}, using annual data for the period 2007--2017 on 721 molecules. Estimates of the "relative utilization index" are shown in [Fig. 2](#fig2){ref-type="fig"}. These estimates indicate that utilization of a drug reaches a peak about 12--14 years after it was launched. It is used about twice as much then as it was 4 years after launch[14](#fn14){ref-type="fn"}Fig. 2Drug age-utilization profile.Source: Author\'s calculations based on data contained in Health Canada Drug Product Database and IQVIA MIDAS database.Fig. 2

Due to gradual diffusion of new drugs, the maximum impact of a drug on disease burden is likely to occur many years after it was launched, but the peak effect could occur either more than or less than 12--14 years after launch. The lag might be longer because some drugs for chronic diseases (e.g. statins) may have to be consumed for several years to achieve full effectiveness. But the lag might be shorter because the impact of a drug on disease burden is likely to depend on its quality (or effectiveness) as well as on its quantity (utilization), and drugs launched more recently are likely to be of higher quality than earlier-vintage drugs. [15](#fn15){ref-type="fn"}^,^[16](#fn16){ref-type="fn"}

As mentioned earlier, in addition to analyzing the impact of new drug launches on DALYs, we will analyze their impact on the number of hospital discharges and on the average length of hospital stays, by estimating the following equations:Where.Δln(DISCHARGES~d~) = ln(DISHARGES~d,2016~/DISCHARGES~d,2000~)Δln(ALOS~d~) = ln(ALOS~d,2016~/ALOS~d,2000~)DISCHARGES~dt~ = the number of hospital discharges for disease d in year t (t = 2000, 2016)ALOS~dt~ = average length (number of days) of hospital stays for disease d in year t

Eqs. [(6)](#fd6){ref-type="disp-formula"}, [(7)](#fd7){ref-type="disp-formula"} will be estimated by weighted least squares, weighting by (DISCHARGES~d,2000~ + DISCHARGES~d,2016~)/2.

3. Data sources {#sec3}
===============

*Disease burden data.* Age-standardized rates of DALY, YLL, and YLD, by disease and year, were constructed using data obtained from the World Health Organization\'s *Disease Burden Database* ([@bib37]).[17](#fn17){ref-type="fn"} The disease classification used in the *Disease Burden Database* is described in Annex Table A of [@bib38]. Age-standardized rates (per 100,000 population) of Disability-Adjusted Life-Years lost (DALYs), Years of Life Lost (YLLs), and Years of Healthy Life Lost due to Disability (YLDs), by cause, in 2000 and 2016 are shown in Appendix [Table 1](#tbl1){ref-type="table"}.

*Drug launch data.* Health Canada\'s Drug Products Database ([@bib14]) was used to determine the years in which (WHO ATC 5th-level) chemical substances first received market authorization in Canada.

*Drug indications data.* Indications (coded by ICD-10) of chemical substances were obtained from [Theriaque](http://www.theriaque.org/apps/contenu/accueil.php){#intref0010}, a database produced by the French [@bib6].[18](#fn18){ref-type="fn"} The number of (WHO ATC5) chemical substances ever launched, by cause, during 1980--2016 are shown in Appendix [Table 2](#tbl2){ref-type="table"}.Table 2Estimates of β~k~ parameters of eq. [(4)](#fd4){ref-type="disp-formula"}.Table 2A. DALYs (disability-adjusted life-years)rowlagEstimateStd. Err.t Valuep-valueNmean (regressor)β~k~ \* mean (regressor)10**−0.2870.118−2.440.016**1330.234−0.06721−0.0070.112−0.060.9501310.255−0.00232−0.0710.116−0.610.5421300.270−0.01943−0.1600.105−1.520.1311300.295−0.04754**−0.2550.096−2.660.009**1290.331−0.08465**−0.1760.081−2.190.031**1280.361−0.06476−0.0940.073−1.280.2031280.396−0.03787−0.1280.074−1.740.0851270.422−0.05498−0.1370.070−1.950.0531250.442−0.061109**−0.2570.073−3.510.001**1240.473−0.1221110**−0.2460.078−3.160.002**1230.482−0.1181211**−0.2510.066−3.820.000**1230.516−0.1291312**−0.2470.066−3.740.000**1220.529−0.1311413**−0.3070.063−4.88\<.0001**1220.536−0.1641514**−0.3310.060−5.48\<.0001**1210.551−0.1821615**−0.4140.072−5.77\<.0001**1190.557−0.2311716**−0.3340.063−5.27\<.0001**1160.605−0.2021817**−0.3230.056−5.81\<.0001**1160.637−0.2061918**−0.3150.055−5.76\<.0001**1160.633−0.2002019**−0.3110.053−5.83\<.0001**1120.640−0.1992120**−0.2810.053−5.28\<.0001**1120.649−0.182**B. YLLs (years of life lost)rowlagEstimateStd. Err.t Valuep-valueNmean(regressor)**β**~k~ \* mean(regressor)**220−0.0700.140−0.500.6191330.285−0.0202310.2310.1231.880.0631310.2930.0682420.1110.1350.830.4101300.3000.033253−0.0310.125−0.250.8041300.331−0.010264−0.1830.114−1.610.1111290.371−0.068275−0.0850.092−0.930.3571280.409−0.035286−0.0150.088−0.170.8641280.446−0.007297−0.0530.090−0.590.5551270.477−0.025308−0.0990.087−1.130.2621250.495−0.049319**−0.2000.092−2.170.033**1240.533−0.1073210−0.1840.096−1.920.0581230.536−0.0993311**−0.2720.082−3.320.001**1230.568−0.1553412**−0.3030.085−3.560.001**1220.576−0.1743513**−0.3760.082−4.59\<.0001**1220.600−0.2253614**−0.4190.077−5.41\<.0001**1210.621−0.2603715**−0.5130.103−4.98\<.0001**1190.635−0.3263816**−0.2380.087−2.720.008**1160.722−0.1723917**−0.2000.078−2.560.012**1160.788−0.1574018**−0.2120.077−2.750.007**1160.781−0.1654119**−0.1780.074−2.420.018**1120.806−0.1444220**−0.1530.070−2.180.032**1120.807−0.124**C. YLDs (years lost due to disability)rowlagEstimateStd. Err.t Valuep-valueNmean(regressor)**β**~k~ \* mean(regressor)**430−0.1160.071−1.630.1061330.173−0.0204410.0140.0590.230.8151310.2100.003452−0.0080.057−0.130.8941300.234−0.002463−0.0270.051−0.520.6041300.253−0.007474−0.0520.048−1.090.2791290.284−0.015485−0.0530.044−1.210.2281280.305−0.0164960.0080.0350.220.8271280.3370.003507−0.0010.035−0.020.9871270.3580.0005180.0110.0260.430.6691250.3790.004529**−0.0640.027−2.370.019**1240.401−0.0265310**−0.0580.029−2.000.049**1230.417−0.0245411−0.0450.024−1.920.0581230.453−0.0205512−0.0420.022−1.900.0611220.472−0.0205613**−0.0450.022−2.010.047**1220.458−0.0215714−0.0420.022−1.900.0601210.467−0.0205815**−0.0680.025−2.730.007**1190.465−0.0325916**−0.0680.026−2.650.009**1160.468−0.0326017**−0.0720.025−2.850.005**1160.458−0.0336118**−0.0630.024−2.610.010**1160.457−0.0296219**−0.0660.026−2.560.012**1120.444−0.0296320**−0.0560.025−2.210.030**1120.463−0.026

*Drug utilization and expenditure data.* Data on the quantity (number of standard units) and value (in USD) of prescription drugs sold in Canada, by chemical substance and year (2007--2017) were obtained from the IQVIA MIDAS database.

*Cancer incidence data.* Data on the number of new cases of primary cancer, by cancer site and year, were obtained from [@bib34].

*Hospitalization data.* Data on the number of hospital discharges and average length of stay, by diagnosis, in 2000 and 2016, were obtained from the *OECD Health Statistics database* ([@bib27]). The disease classification scheme is provided in [@bib28]. The number of hospital discharges and average length of stay (in days), by cause, in 2000 and 2016 are shown in Appendix [Table 3](#tbl3){ref-type="table"}.Table 3Estimates of β~k~ parameters of eqs. [(6)](#fd6){ref-type="disp-formula"}, [(7)](#fd7){ref-type="disp-formula"}.Table 3A. DischargesrowlagEstimateStd. Err.t Valuep-valueNmean (regressor)β~k~ \* mean (regressor)100.2360.2600.910.369610.1990.047210.2660.2521.060.294610.2110.056320.2560.2461.040.301610.2230.057430.1640.2120.770.443610.2540.042540.1490.1920.780.439610.2920.044650.1010.1750.580.566610.3160.032760.0920.1800.510.612610.3270.030870.1090.1830.600.552610.3550.039980.1410.1670.840.403610.3800.0541090.1160.1590.730.470610.4220.04911100.1170.1660.710.483610.4240.05012110.0920.1520.610.547610.4660.04313120.0860.1490.580.564610.4910.04214130.0960.1460.650.516610.5120.04915140.1150.1400.830.411610.5390.06216150.1670.1571.060.294600.5550.09317160.1510.1590.960.343600.5650.08618170.0950.1400.680.499600.6020.05719180.0530.1350.390.698580.6080.03220190.0750.1420.520.602580.6060.04521200.0800.1380.580.567580.6190.049  B. ALOS**rowlagEstimateStd. Err.t Valuep-valueNmean(regressor)**β**~k~ \* mean(regressor)**220**−0.4310.157−2.740.008**610.199−0.086231**−0.4170.153−2.730.008**610.211−0.088242**−0.4520.147−3.080.003**610.223−0.101253**−0.4180.124−3.360.001**610.254−0.106264**−0.3830.112−3.410.001**610.292−0.112275**−0.3410.102−3.330.002**610.316−0.108286**−0.3160.108−2.940.005**610.327−0.103297**−0.3170.109−2.890.005**610.355−0.112308**−0.3020.100−3.020.004**610.380−0.115319**−0.2670.096−2.790.007**610.422−0.1133210**−0.2680.100−2.670.010**610.424−0.1143311**−0.2420.092−2.630.011**610.466−0.1133412**−0.2370.090−2.630.011**610.491−0.1163513**−0.2650.087−3.030.004**610.512−0.1363614**−0.2710.082−3.290.002**610.539−0.1463715**−0.3110.093−3.350.001**600.555−0.1733816**−0.3150.093−3.380.001**600.565−0.1783917**−0.2780.082−3.390.001**600.602−0.1674018**−0.2820.078−3.620.001**580.608−0.1714119**−0.2750.083−3.300.002**580.606−0.1664220**−0.2510.082−3.060.003**580.619−0.155

4. Results {#sec4}
==========

Estimates of β~k~ parameters of eq. [(4)](#fd4){ref-type="disp-formula"} are shown in [Table 2](#tbl2){ref-type="table"}. In Panel A of [Table 2](#tbl2){ref-type="table"}, the dependent variable is Δln(DALY~d~) = ln(DALY~d,2016~/DALY~d,2000~). The estimate in each row of the table is from a separate model. Rows 1--21 show estimates for assumed values of 0, 1, 2, ..., 20 years of the lag (k) from drug launch to disease burden. The point estimates and 95% confidence intervals are also plotted (on an inverted scale) in Panel A of [Fig. 3](#fig3){ref-type="fig"}, where solid markers denote significant (p-value \< .05) estimates and hollow markers represent insignificant estimates. For k ≤ 8, only 3 of the 9 estimates are statistically significant. This is not surprising since, as discussed earlier, utilization of recently-launched drugs tends to be quite low, and there may also be a lag from drug utilization to disease burden reduction. However, for k ≥ 9, all 12 β~k~ estimates are negative and statistically significant: the number of DALYs lost is significantly inversely related to the number of drugs that had ever been launched 9--20 years earlier. The magnitude of the estimates tends to increase as k increases, until k = 15, when it starts to decline. The launch of a drug had the largest (most negative) impact on the number of DALYs lost 15 years after it was launched.Fig. 3Estimates of β~k~ parameters of eq. [(4)](#fd4){ref-type="disp-formula"}.Fig. 3

Panel A of [Fig. 4](#fig4){ref-type="fig"} shows a comparison of the relative utilization and DALY β~k~ estimate profiles. Utilization of a drug tends to rise until 12 years after launch, remains stable for 3 years, and then starts to decline. The β~k~ estimates exhibit some volatility in years 0--6, but then generally increase in magnitude until year 15, and begin to decline the year after utilization begins to decline. The correlation between these two profiles is highly statistically significant (correlation = −0.58; p-value = .006).Fig. 4Comparison of relative utilization and β~k~ estimate profiles.Fig. 4

[Fig. 5](#fig5){ref-type="fig"} is a bubble plot depicting the relationship across diseases between the 1985--2001 percentage increase in the number of drugs ever launched, and the 2000--2016 percentage change in the age-standardized DALY rate. It is clear from the figure that ischemic heart disease is a highly influential observation. Although the fact that an observation is influential does not necessarily mean that it should be excluded, we estimated the model when that observation was excluded. Exclusion of that observation reduced the point estimate of β~15~ by 36% (from −0.414 to −0.265), but the estimate remained highly significant (t-value = 4.93; p-value \< .0001).[19](#fn19){ref-type="fn"}Fig. 5Relationship across diseases between % increase in number of drugs ever launched, 1985--2001, and % change in age-standardized DALY rate, 2000--2016.Bubble area is proportional to (DALY~c,2000~ + DALY~c,2016~)/2.Fig. 5

Another apparently influential observation is diabetes. This observation is *weakening* the relationship between drug launches and DALY reduction: despite a large percentage increase in the number of diabetes drugs, the burden of diabetes did not decline by an unusually large amount. This may be due to a significant increase in the prevalence of diabetes.[20](#fn20){ref-type="fn"} Appendix [Fig. 1](#fig1){ref-type="fig"} shows that the prevalence of diabetes in Canada increased significantly between 2000/2001 and 2008. When we exclude both diabetes and ischemic heart disease from the sample, the point estimate of β~15~ (−0.385) is very close to the estimate reported in row 16 of [Table 2](#tbl2){ref-type="table"}, and is highly significant (t-value = 5.69; p-value \< .0001).

We also estimated an alternative functional form (semi-logarithmic as opposed to log-log) of the relationship between drug launches and subsequent DALY reduction. These estimates are shown in [Appendix Table 4](#dtbl4){ref-type="table"}. Twenty of the 21 coefficients are negative and significant. There is little evidence of an inverted U-shaped profile, and the maximum magnitude of the effect (β~k~ \* mean (regressor)) in the semi-logarithmic model is only 38% as large as the maximum magnitude of the effect in the log-log model. But the fit of the semi-logarithmic model is inferior to the fit of the log-log model. When we include both ln (CUM_DRUG~d,2001~/CUM_DRUG~d,1985~) and (CUM_DRUG~d,2001~ - CUM_DRUG~d,1985~) in the model, as suggested by [@bib9], the coefficient on the former regressor is significant, but the coefficient on the latter regressor is not. This indicates that the log-log functional form is more appropriate than the semi-logarithmic functional form.[21](#fn21){ref-type="fn"}

Now we will briefly summarize estimates of models of the two components of DALY, YLL and YLD.[22](#fn22){ref-type="fn"} In Panel B of [Table 2](#tbl2){ref-type="table"}, the dependent variable is Δln(YLL~d~) = ln(YLL~d,2016~/YLL~d,2000~). Rows 22--42 show estimates for assumed values of 0, 1, 2, ..., 20 years of the lag (k) from drug launch to disease burden. The point estimates and 95% confidence intervals are also plotted (on an inverted scale) in Panel B of [Fig. 3](#fig3){ref-type="fig"}. For k ≤ 10, only 1 of the 11 estimates is statistically significant. However, for k ≥ 11, all 10 β~k~ estimates are negative and statistically significant: the number of YLLs is significantly inversely related to the number of drugs that had ever been launched 11--20 years earlier. Once again, the magnitude of the estimates tends to increase as k increases, until k = 15, when it starts to decline. The launch of a drug had the largest (most negative) impact on the number of YLLs lost 15 years after it was launched. Panel B of [Fig. 4](#fig4){ref-type="fig"} shows a comparison of the relative utilization and YLL β~k~ estimate profiles. Like the DALY β~k~ estimates, the YLL β~k~ estimates exhibit some volatility in years 0--6, but then generally increase in magnitude until year 15, and begin to decline the year after utilization begins to decline. The correlation between these two profiles is again highly statistically significant (correlation = −0.78; p-value \< .001).

In Panel C of [Table 2](#tbl2){ref-type="table"}, the dependent variable is Δln(YLD~d~) = ln(YLD~d,2016~/YLD~d,2000~). The point estimates and 95% confidence intervals are also plotted (on an inverted scale) in Panel C of [Fig. 3](#fig3){ref-type="fig"}. For k ≤ 8, none of the 9 estimates are statistically significant. For 9 ≤ k ≤ 14, 3 out of 6 β~k~ estimates are negative and significant. For 15 ≤ k ≤ 20, 6 out of 6 β~k~ estimates are negative and significant. This indicates that the number of years lost due to disability was reduced by drugs that had been launched up until 15--20 years earlier.

The estimates in [Table 2](#tbl2){ref-type="table"} imply that most of the DALY reduction from new drug launches was due to a reduction in YLL. The estimates of β~15~ in rows 16, 37, and 58 imply that new drug launches during 1986--2001 reduced DALYs in 2016 by 21% (= 1 -- exp (-0.231)), reduced YLLs in 2016 by 28%, and reduced YLDs in 2016 by 3%.[23](#fn23){ref-type="fn"} There will be additional discussion of the magnitudes of these effects in the next section.

The last estimates we will present are estimates of β~k~ from the hospital discharges and average length of stay equations, eqs. [(6)](#fd6){ref-type="disp-formula"}, [(7)](#fd7){ref-type="disp-formula"}. Panel A of [Table 3](#tbl3){ref-type="table"} shows estimates of β~k~ from the hospital discharges equation, eq. [(6)](#fd6){ref-type="disp-formula"}. None of the estimates are statistically significant; we see no evidence that new drug launches reduced the number of people discharged from (or admitted to) hospitals. However, since there is strong evidence that new drug launches reduced mortality, they may have increased the number of people "at risk" of being hospitalized, so new drug launches may have reduced the number of hospital discharges per person at risk of being hospitalized.

Panel B of [Table 3](#tbl3){ref-type="table"} shows estimates of β~k~ from the average length of hospital stay equation, eq. [(7)](#fd7){ref-type="disp-formula"}. All 21 estimates are negative and highly significant (p-value ≤ .011), indicating that medical conditions for which there were more new drug launches had smaller increases in average length of stay (ALOS).[24](#fn24){ref-type="fn"} In contrast to the DALY and YLL estimates, the magnitudes of the ALOS estimates are larger for more recent drug launches. Perhaps uptake of new drugs is more rapid among hospitalized patients than it is among other patients. However, the overall impact of new drug launches (β~k~ \* mean(Δln(CUM_DRUG_k))) is highest for k = 16: new drugs launched during 1984--2000 had the largest (most negative) effect on ALOS in 2016. The estimate in row 38 of [Table 3](#tbl3){ref-type="table"} indicates that those drug launches reduced ALOS in 2016 by 16% (= 1 -- exp(-0.178)).

5. Discussion {#sec5}
=============

The estimates of the DALY model shown in Panel A of [Table 2](#tbl2){ref-type="table"} and [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, in conjunction with other data, may be used to calculate the reduction in DALYs lost in 2016 attributable to previous drug launches and the average cost per DALY gained. DALYs are most significantly inversely related to the number of drugs that had ever been launched 15 years earlier. The estimate of β~15~ in row 16 of [Table 2](#tbl2){ref-type="table"} indicates that drugs launched during 1986--2001 reduced the mean 2000--2016 log change in DALYs lost by −0.231. This implies that, in the absence of those drug launches, DALYs lost in 2016 would have been 26.0% (= 1 - exp(-0.231)) higher. As shown in [Table 1](#tbl1){ref-type="table"}, the total number of DALYs lost in 2016 was 8.896 million, so we estimate that drugs launched during 1986--2001 reduced the number of DALYs lost in 2016 by 2.31 million. If those drugs had not been launched, the total number of DALYs lost in 2016 would have been 11.21 million. Similar calculations based on the YLL and YLD estimates imply that almost all (93%) of the reduction in DALYs was due to a reduction in YLL.

As noted earlier (see [Table 1](#tbl1){ref-type="table"}), the age-standardized DALY rate declined by 14.4% between 2000 and 2016. The estimate of the model in row 16 of [Table 2](#tbl2){ref-type="table"} indicates that, if no drugs had been launched during 1986--2001, the age-standardized DALY rate would not have declined; it might even have increased.[25](#fn25){ref-type="fn"} [Fig. 6](#fig6){ref-type="fig"} compares actual % declines in age-standardized DALY, YLL, and YLD rates, 2000--2016 to estimated % declines attributable to drugs launched during 1986--2001.Fig. 6Actual vs. estimated % declines in age-standardized DALY, YLL, and YLD rates, 2000--2016.Fig. 6

According to unpublished IQVIA data, expenditure in Canada in 2016 on drugs launched during 1986--2001 was 6.57 billion USD.[26](#fn26){ref-type="fn"} This expenditure estimate, along with our estimate of the reduction in DALYs lost, implies that pharmaceutical expenditure per DALY gained in 2016 from drugs launched during 1986--2001 was 2842 USD (= 6.57 billion USD/2.31 million DALYs).[27](#fn27){ref-type="fn"} As noted by [@bib2], authors writing on behalf of the WHO\'s *Choosing Interventions that are Cost--Effective* project (WHO-CHOICE) suggested in 2005 that "interventions that avert one DALY for less than average per capita income for a given country or region are considered very cost--effective; interventions that cost less than three times average per capita income per DALY averted are still considered cost--effective." Canada\'s per capita GDP was 42,158 USD in 2016, so these estimates indicate that the new drugs launched during 1986--2001 were very cost--effective, overall.

Several considerations suggest that 2842 USD may be an overestimate of the true net cost in 2016 per DALY of drugs launched during 1986--2001. First, that estimate is based on drug cost measured at invoice price levels; rebates and discounts are not reflected.[28](#fn28){ref-type="fn"} Second, a previous study based on U.S. data ([@bib22]) showed that about 25% of the cost of new drugs is offset by reduced expenditure on old drugs.[29](#fn29){ref-type="fn"} Third, our estimates indicated that, if no drugs had been launched during 1986--2001, the average length of 2016 hospital stays would have been about 16% higher. This suggests that hospital expenditure might have been 16% higher. According to the [@bib5], hospital expenditure in 2016 was 51.30 billion USD (= 66.63 billion CAD at a 0.77 USD/CAD exchange rate), so hospital expenditure might have been 8.21 billion USD (= 16% \* 51.30 billion USD) higher. The reduction in hospital expenditure due to shorter average length of stay may have been larger than the expenditure on the drugs responsible for shorter hospital stays.

6. Summary {#sec6}
==========

In this study, we performed an econometric assessment of the role that pharmaceutical innovation---the introduction and use of new drugs---has played in reducing the burden of disease in Canada, by investigating whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. Since utilization of a drug reaches a peak about 12--14 years after it was launched, we allowed for considerable lags in the relationship between new drug launches and the burden of disease.

We analyzed the impact of new drug launches on a comprehensive measure of disease burden---the age-standardized disability-adjusted life-years lost (DALY) rate---and on its two components: the age-standardized years of life lost (YLL) and years lost to disability (YLD) rates. We also analyzed the impact of new drug launches on the number of hospital discharges and on the average length of hospital stays.

We found that the number of DALYs lost is significantly inversely related to the number of drugs that had ever been launched 9--20 years earlier, and that the number of YLLs is significantly inversely related to the number of drugs that had ever been launched 11--20 years earlier. The launch of a drug had the largest (most negative) impact on the number of DALYs and YLLs 15 years after it was launched.

The estimates indicated that if no drugs had been launched during 1986--2001, the age-standardized DALY rate would not have declined between 2000 and 2016; it might even have increased. Almost all (93%) of the reduction in DALYs was due to a reduction in YLL. The estimates implied that new drug launches during 1986--2001 reduced DALYs in 2016 by 21%, reduced YLLs in 2016 by 28%, and reduced YLDs in 2016 by 3%.

We estimated that drugs launched during 1986--2001 reduced the number of DALYs lost in 2016 by 2.31 million. Expenditure in 2016 on drugs launched during 1986--2001 per DALY gained in 2016 from those drugs was 2842 USD. Interventions that avert one DALY for less than average per capita income for a given country or region are generally considered to be very cost--effective; Canada\'s per capita GDP was 42,158 USD in 2016, so our estimates indicate that the new drugs launched during 1986--2001 were very cost--effective, overall.

Due to data limitations, we were unable to control for non-pharmaceutical medical innovations. Evidence from previous studies suggests that this is unlikely to cause significant bias in our estimates, because (1) the vast majority (88%) of private U.S. biomedical research funding came from pharmaceutical and biotechnology firms, and (2) non-pharmaceutical medical innovation does not appear to be positively correlated across diseases with pharmaceutical innovation. But, *arguendo*, suppose that drugs launched during 1986--2001 reduced the number of DALYs lost in 2016 by half as much as we estimated: by 1.155 million, instead of 2.31 million, and that the other half was due to new medical devices. Then 2016 expenditure on those drugs per 2016 DALY reduction would be twice as high as we estimated: \$5684, instead of \$2842. Even this higher figure would indicate that the new drugs launched during 1986--2001 were very cost--effective in 2016.

Moreover, 2842 USD may be an overestimate of the true net cost in 2016 per DALY of drugs launched during 1986--2001. A previous study based on U.S. data showed that about 25% of the cost of new drugs is offset by reduced expenditure on old drugs. Also, our estimates indicated that, if no drugs had been launched during 1986--2001, the average length of 2016 hospital stays would have been about 16% higher. The reduction in hospital expenditure due to shorter average length of stay may have been larger than the expenditure on the drugs responsible for shorter hospital stays.
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Appendix Table 1Age-standardized rates (per 100,000 population) of Disability-Adjusted Life-Years lost (DALYs), Years of Life Lost (YLLs), and Years of Healthy Life Lost due to Disability (YLDs), by cause, Canada, 2000 and 2016.Appendix Table 1WHO Global Health Estimates causeDALYYLLYLD2000201620002016200020160 All Causes25,087.321,463.014,818.311,121.210,269.010,341.910 Communicable, maternal, perinatal and nutritional conditions1,181.71,142.7824.4757.2357.3385.520 Infectious and parasitic diseases340.8304.5273.1230.467.774.130 Tuberculosis11.05.99.95.01.10.940 STDs excluding HIV14.516.51.32.613.213.950 Syphilis2.64.40.42.12.22.360 Chlamydia2.12.10.20.11.92.070 Gonorrhoea1.61.50.50.31.11.280 Trichomoniasis3.33.40.00.03.33.485 Genital herpes2.62.70.00.02.62.790 Other STDs2.42.40.20.12.22.2100 HIV/AIDS107.959.585.032.422.927.1110 Diarrhoeal diseases26.666.213.450.913.315.3120 Childhood-cluster diseases2.11.21.20.40.90.8130 Whooping cough1.81.00.90.30.90.8140 Diphtheria0.00.00.00.00.00.0150 Measles0.20.10.20.10.00.0160 Tetanus0.00.00.00.00.00.0170 Meningitis19.811.816.78.43.13.4180 Encephalitis25.325.321.821.33.53.9185 Hepatitis22.011.420.310.71.70.6186 Acute hepatitis A5.22.04.51.70.80.3190 Acute hepatitis B7.55.76.75.40.80.3200 Acute hepatitis C0.00.00.00.00.00.0205 Acute hepatitis E9.23.79.13.70.10.0210 Parasitic and vector diseases2.20.91.60.30.70.5220 Malaria0.00.00.00.00.00.0230 African trypanosomiasis0.00.00.00.00.00.0240 Chagas disease0.20.20.00.00.20.2250 Schistosomiasis0.00.00.00.00.00.0260 Leishmaniasis0.00.00.00.00.00.0270 Lymphatic filariasis0.00.00.00.00.00.0280 Onchocerciasis0.00.00.00.00.00.0285 Cysticercosis1.10.10.90.00.20.1295 Echinococcosis0.90.30.60.00.20.3300 Dengue0.00.00.00.00.00.0310 Trachoma0.00.00.00.00.00.0315 Yellow fever0.00.00.00.00.00.0320 Rabies0.10.20.10.20.00.0330 Intestinal nematode infections0.00.00.00.00.00.0340 Ascariasis0.00.00.00.00.00.0350 Trichuriasis0.00.00.00.00.00.0360 Hookworm disease0.00.00.00.00.00.0362 Food-bourne trematodes0.00.00.00.00.00.0365 Leprosy0.00.00.00.00.00.0370 Other infectious diseases109.3105.9102.098.37.47.6380 Respiratory infections376.1348.3245.3218.0130.7130.3390 Lower respiratory infections248.2220.4243.8216.04.34.4400 Upper respiratory infections102.2103.20.91.5101.3101.6410 Otitis media25.724.80.60.525.124.3420 Maternal conditions7.66.56.04.81.51.6490 Neonatal conditions383.5415.2278.4287.7105.1127.5500 Preterm birth complications226.7242.1156.7150.970.091.2510 Birth asphyxia and birth trauma75.768.759.350.416.418.3520 Neonatal sepsis and infections28.928.413.914.615.013.8530 Other neonatal conditions52.176.048.571.83.64.2540 Nutritional deficiencies73.868.321.516.352.252.0550 Protein-energy malnutrition12.911.88.56.64.45.1560 Iodine deficiency12.312.40.00.012.312.3570 Vitamin A deficiency0.00.00.00.00.00.0580 Iron-deficiency anaemia45.542.710.18.435.534.3590 Other nutritional deficiencies3.11.42.91.20.10.2600 Noncommunicable diseases21,373.318,102.512,347.79,052.09,025.79,050.6610 Malignant neoplasms4,885.63,750.24,734.13,601.0151.5149.2620 Mouth and oropharynx cancers87.374.784.172.03.22.7621 Lip and oral cavity44.939.242.637.42.31.8622 Nasopharynx10.98.010.67.80.30.2623 Other pharynx31.527.530.926.90.70.6630 Oesophagus cancer122.0102.9120.7101.71.31.3640 Stomach cancer162.5107.3158.3103.54.33.8650 Colon and rectum cancers536.3427.1516.5408.519.818.6660 Liver cancer100.5127.599.6126.01.01.5661 Liver cancer secondary to hepatitis B16.621.016.520.80.10.1662 Liver cancer secondary to hepatitis C36.647.636.547.40.10.2663 Liver cancer secondary to alcohol use30.838.730.538.20.40.5664 Other liver cancer16.520.316.019.60.40.7670 Pancreas cancer222.9204.8220.7202.62.32.2680 Trachea, bronchus, lung cancers1,261.9943.21,247.8930.014.113.2690 Melanoma and other skin cancers91.688.686.882.54.86.0691 Malignant skin melanoma78.872.274.366.84.55.3692 Non-melanoma skin cancer12.816.412.515.70.30.7700 Breast cancer484.8326.9456.5300.928.426.0710 Cervix uteri cancer41.934.839.732.92.21.9720 Corpus uteri cancer60.760.456.855.83.84.6730 Ovary cancer115.591.4112.388.63.22.8740 Prostate cancer244.3159.9220.6138.823.721.1742 Testicular cancer7.57.86.66.70.91.1745 Kidney cancer117.393.3113.889.83.53.4750 Bladder cancer107.789.3101.583.36.26.0751 Brain and nervous system cancers183.6166.4181.2163.62.42.8752 Gallbladder and biliary tract cancer38.924.237.923.51.00.7753 Larynx cancer44.722.243.221.01.51.2754 Thyroid cancer12.212.410.110.02.12.3755 Mesothelioma26.622.326.121.80.50.5760 Lymphomas, multiple myeloma336.5229.0326.0216.810.512.2761 Hodgkin lymphoma18.212.517.011.11.21.4762 Non-Hodgkin lymphoma233.5145.6226.8137.56.78.1763 Multiple myeloma84.970.982.268.12.72.8770 Leukaemia192.9153.2186.3145.96.67.3780 Other malignant neoplasms285.4180.6281.1174.84.35.8790 Other neoplasms107.575.898.764.38.811.5800 Diabetes mellitus851.9699.9414.5282.8437.5417.1810 Endocrine, blood, immune disorders230.9232.1162.2159.568.772.6811 Thalassaemias10.010.31.51.18.59.2812 Sickle cell disorders and trait4.04.21.61.72.42.5813 Other haemoglobinopathies and haemolytic anaemias19.213.417.111.62.11.8814 Other endocrine, blood and immune disorders197.7204.2142.0145.155.859.1820 Mental and substance use disorders2,848.62,973.0278.1293.52,570.52,679.4830 Depressive disorders662.0633.00.00.0662.0633.0831 Major depressive disorder499.3469.00.00.0499.3469.0832 Dysthymia162.7164.00.00.0162.7164.0840 Bipolar disorder176.4171.31.31.1175.1170.3850 Schizophrenia226.9225.38.84.3218.1220.9860 Alcohol use disorders280.5272.594.177.4186.4195.1870 Drug use disorders536.6627.1164.8204.7371.7422.4871 Opioid use disorders348.0419.3120.7142.3227.2277.0872 Cocaine use disorders61.172.713.522.147.650.6873 Amphetamine use disorders19.423.64.77.814.615.8874 Cannabis use disorders31.024.20.00.031.024.2875 Other drug use disorders77.187.425.932.551.254.9880 Anxiety disorders482.4513.50.00.0482.4513.5890 Eating disorders54.860.52.83.652.156.9900 Autism and Asperger syndrome138.9140.40.00.0138.9140.4910 Childhood behavioural disorders79.978.90.00.079.978.9911 Attention deficit/hyperactivity syndrome12.312.20.00.012.312.2912 Conduct disorder67.566.70.00.067.566.7920 Idiopathic intellectual disability32.670.36.42.526.367.8930 Other mental and behavioural disorders177.7180.30.00.0177.7180.3940 Neurological conditions1,596.61,761.2706.3874.6890.3886.5950 Alzheimer disease and other dementias501.6708.7371.5559.2130.1149.5960 Parkinson disease90.995.865.870.025.225.8970 Epilepsy96.787.134.333.362.453.7980 Multiple sclerosis86.088.543.535.742.452.8990 Migraine507.9480.40.00.0507.9480.41000 Non-migraine headache102.299.50.00.0102.299.51010 Other neurological conditions211.2201.2191.1176.420.124.81020 Sense organ diseases893.3911.00.60.6892.7910.51030 Glaucoma8.08.00.10.08.08.01040 Cataracts29.915.50.00.029.915.51050 Uncorrected refractive errors161.3164.20.00.0161.3164.21060 Macular degeneration12.811.00.00.012.811.01070 Other vision loss46.137.50.00.046.137.51080 Other hearing loss530.4569.30.00.0530.4569.21090 Other sense organ disorders104.8105.60.50.6104.3105.01100 Cardiovascular diseases4,654.42,733.94,049.12,200.5605.3533.31110 Rheumatic heart disease28.519.526.417.72.11.81120 Hypertensive heart disease58.162.247.552.710.69.51130 Ischaemic heart disease2,769.01,416.02,668.81,331.7100.284.31140 Stroke985.7609.9761.5400.9224.2209.01141 Ischaemic stroke639.4391.5450.1220.2189.3171.31142 Haemorrhagic stroke346.2218.4311.4180.734.937.81150 Cardiomyopathy, myocarditis, endocarditis130.7103.3114.889.515.913.81160 Other circulatory diseases682.5523.0430.0308.1252.4214.91170 Respiratory diseases1,147.6992.7743.9611.5403.8381.21180 Chronic obstructive pulmonary disease664.4540.8583.6455.880.885.01190 Asthma337.8296.927.015.1310.7281.91200 Other respiratory diseases145.4155.0133.2140.612.214.41210 Digestive diseases637.6592.5553.6504.684.088.01220 Peptic ulcer disease37.533.524.519.013.014.51230 Cirrhosis of the liver232.1251.8215.3234.516.817.31231 Cirrhosis due to hepatitis B30.434.029.232.81.21.21232 Cirrhosis due to hepatitis C54.557.150.052.54.54.61233 Cirrhosis due to alcohol use98.7106.192.599.66.36.41234 Other liver cirrhosis48.654.743.649.64.95.11240 Appendicitis3.83.32.72.21.11.11241 Gastritis and duodenitis19.520.23.83.015.617.21242 Paralytic ileus and intestinal obstruction32.031.330.930.11.11.21244 Inflammatory bowel disease27.618.118.28.89.49.41246 Gallbladder and biliary diseases27.225.922.721.14.64.81248 Pancreatitis29.625.225.921.33.73.91250 Other digestive diseases228.3183.1209.6164.618.718.61260 Genitourinary diseases502.7447.1217.4159.8285.2287.31270 Kidney diseases284.6218.3179.8113.8104.8104.51271 Acute glomerulonephritis0.40.30.40.30.00.01272 Chronic kidney disease due to diabetes141.1103.687.150.754.052.91273 Other chronic kidney disease143.0114.492.362.850.751.61280 Benign prostatic hyperplasia61.763.51.92.759.860.81290 Urolithiasis5.96.51.41.94.54.61300 Other urinary diseases40.947.333.940.76.96.61310 Infertility9.79.60.00.09.79.61320 Gynecological diseases100.0101.90.40.799.5101.21330 Skin diseases308.4313.715.617.1292.8296.61340 Musculoskeletal diseases1,964.11,950.883.470.71,880.71,880.11350 Rheumatoid arthritis105.3116.816.511.288.9105.61360 Osteoarthritis245.4251.86.14.2239.4247.71370 Gout30.230.80.40.529.930.41380 Back and neck pain893.5872.52.23.3891.3869.21390 Other musculoskeletal disorders689.7678.958.351.7631.3627.21400 Congenital anomalies366.4307.3254.6192.5111.8114.71410 Neural tube defects25.922.312.28.013.714.31420 Cleft lip and cleft palate0.90.80.10.10.80.81430 Down syndrome23.828.516.120.87.77.71440 Congenital heart anomalies115.373.3102.059.913.313.51450 Other chromosomal anomalies45.347.532.835.312.512.21460 Other congenital anomalies155.2134.891.468.663.866.21470 Oral conditions342.7343.60.61.3342.1342.41480 Dental caries27.126.90.00.027.126.91490 Periodontal disease82.883.60.10.182.783.61500 Edentulism175.7175.00.10.1175.6174.91502 Other oral disorders57.158.10.51.156.656.91505 Sudden infant death syndrome35.017.635.017.60.00.0Appendix Table 2Number of (WHO ATC5) chemical substances ever launched, by cause, Canada, 1980--2016.Appendix Table 2WHO Global Health Estimates cause1980198619921998200420102016All chemical substances82810331276161418252000223230 Tuberculosis1010101515151550 Syphilis444555560 Chlamydia555555570 Gonorrhoea67101010111180 Trichomoniasis233333385 Genital herpes022444490 Other STDs1222344100 HIV/AIDS01515253440110 Diarrhoeal diseases15172022232526130 Whooping cough3445555140 Diphtheria4667777150 Measles2445555160 Tetanus8101011111111170 Meningitis10172022252728180 Encephalitis0001122186 Acute hepatitis A1113444190 Acute hepatitis B1357101212200 Acute hepatitis C02336615220 Malaria5569999230 African trypanosomiasis0011111250 Schistosomiasis0001111260 Leishmaniasis1122222270 Lymphatic filariasis0111111280 Onchocerciasis0111111295 Echinococcosis0111111310 Trachoma1111111315 Yellow fever1111111320 Rabies0222222340 Ascariasis2233333360 Hookworm disease1122222362 Food-bourne trematodes3334444365 Leprosy2222233370 Other infectious diseases88109127158169177177390 Lower respiratory infections37455662707575400 Upper respiratory infections47536268707273410 Otitis media18202525262727420 Maternal conditions21273437383940500 Preterm birth complications4488899530 Other neonatal conditions11121414141414550 Protein-energy malnutrition2222333560 Iodine deficiency4445555570 Vitamin A deficiency8999999580 Iron-deficiency anaemia556671010590 Other nutritional deficiencies39424547484949620 Mouth and oropharynx cancers1334444630 Oesophagus cancer1446666640 Stomach cancer2457889650 Colon and rectum cancers333661215660 Liver cancer0112233670 Pancreas cancer13566910680 Trachea, bronchus, lung cancers5111319212330691 Malignant skin melanoma34555512692 Non-melanoma skin cancer0000111700 Breast cancer8141828323540710 Cervix uteri cancer1345588720 Corpus uteri cancer0111111730 Ovary cancer6101317171920740 Prostate cancer25812131519742 Testicular cancer3577777745 Kidney cancer1244467750 Bladder cancer691112121212751 Brain and nervous system cancers11121212131314752 Gallbladder and biliary tract cancer0001111754 Thyroid cancer0000013755 Mesothelioma2344466761 Hodgkin lymphoma11151717171720762 Non-Hodgkin lymphoma16242828293442763 Multiple myeloma9131515151824770 Leukaemia16232832354152800 Diabetes mellitus781324354548811 Thalassaemias0000012812 Sickle cell disorders and trait2222222813 Other haemoglobinopathies and haemolytic anaemias8899111515814 Other endocrine, blood and immune disorders84101125149179199216830 Depressive disorders10131923262728840 Bipolar disorder67711111213850 Schizophrenia15161722222525860 Alcohol use disorders11131414141515871 Opioid use disorders0012344880 Anxiety disorders16192426283030890 Eating disorders781111111111900 Autism and Asperger syndrome2222222911 Attention deficit/hyperactivity syndrome1222333912 Conduct disorder0001111920 Idiopathic intellectual disability0001111930 Other mental and behavioural disorders27303749576061950 Alzheimer disease and other dementias0000111960 Parkinson disease781115172021970 Epilepsy15151621232629980 Multiple sclerosis791216171924990 Migraine131315182222221000 Non-migraine headache8910101112121010 Other neurological conditions283135454953551030 Glaucoma71013182020221040 Cataracts11111111050 Uncorrected refractive errors22334551060 Macular degeneration00001451070 Other vision loss111313141619201080 Other hearing loss11111111090 Other sense organ disorders455261737982831110 Rheumatic heart disease121212141414141120 Hypertensive heart disease223144606975801130 Ischaemic heart disease172432455255581140 Stroke4610141517191150 Cardiomyopathy, myocarditis, endocarditis182326262627271160 Other circulatory diseases5975921151281371451180 Chronic obstructive pulmonary disease333647556062691190 Asthma192127333839401200 Other respiratory diseases445372808487941220 Peptic ulcer disease4813161919191230 Cirrhosis of the liver56781214191241 Gastritis and duodenitis00111111242 Paralytic ileus and intestinal obstruction12222221244 Inflammatory bowel disease8911131516171246 Gallbladder and biliary diseases55688881248 Pancreatitis44555551250 Other digestive diseases5871881021041061121270 Kidney diseases263444545963661280 Benign prostatic hyperplasia125699111290 Urolithiasis77777771300 Other urinary diseases404960737882861310 Infertility557101111121320 Gynecological diseases222729313639431330 Skin diseases941111321491711811911350 Rheumatoid arthritis202425283843441360 Osteoarthritis151819212525251370 Gout66666771380 Back and neck pain192224283436371390 Other musculoskeletal disorders576879911051151181410 Neural tube defects11111111440 Congenital heart anomalies00001121450 Other chromosomal anomalies00111111460 Other congenital anomalies7911121213151480 Dental caries44555551490 Periodontal disease91013141415151502 Other oral disorders16202326262727Appendix Table 3Number of hospital discharges and average length of stay (in days), by cause, Canada, 2000 and 2016.Appendix Table 3CauseNumber of hospital dischargesAverage length of stay20002016200020160000 All causes28,85,06230,57,5037.28.10101 Intestinal infectious diseases except diarrhoea14,13116,8014.87.10103 Tuberculosis1,0151,03920.221.80104 Septicaemia9,23026,59011.112.20105 Human immunodeficiency virus \[HIV\] disease1,65294413.416.40106 Other infectious and parasitic diseases16,52220,8356.28.10200 Neoplasms2,15,4142,02,3109.68.40201 Malignant neoplasm of colon, rectum and anus22,08122,34713.710.30202 Malignant neoplasms of trachea, bronchus and lung22,20418,85112.210.70203 Malignant neoplasms of skin1,9912,0126.36.90204 Malignant neoplasm of breast17,7969,8224.54.20205 Malignant neoplasm of uterus5,7307,4246.44.30206 Malignant neoplasm of ovary3,2703,02111.07.80207 Malignant neoplasm of prostate12,48510,4917.14.70208 Malignant neoplasm of bladder10,2148,2816.06.20209 Other malignant neoplasms74,07882,08213.011.00210 Carcinoma in situ3,5613,5553.73.20211 Benign neoplasm of colon, rectum and anus2,2533,0467.45.70212 Leiomyoma of uterus18,5149,9343.62.10213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour21,23721,4445.95.20300 Diseases of the blood and bloodforming organs and certain disorders involving the immune mechanism25,68827,9846.46.60301 Anaemias13,96014,9096.86.50302 Other diseases of the blood and bloodforming organs and certain disorders involving the immune mechanism11,72813,0756.06.70400 Endocrine, nutritional and metabolic diseases64,57378,5808.27.80401 Diabetes mellitus30,02137,12710.09.90402 Other endocrine, nutritional and metabolic diseases34,55241,4536.75.90600 Diseases of the nervous system43,65259,43111.614.00602 Multiple sclerosis1,8561,42515.716.50603 Epilepsy7,88913,0775.76.50604 Transient cerebral ischaemic attacks and related syndromes10,9709,0575.74.50605 Other diseases of the nervous system20,14530,39613.614.40700 Diseases of the eye and adnexa15,4365,8982.33.30701 Cataract1,6622202.02.00702 Other diseases of the eye and adnexa13,7745,6782.33.30800 Diseases of the ear and mastoid process11,9028,5342.73.10900 Diseases of the circulatory system4,34,5323,80,7378.78.00901 Hypertensive diseases12,3346,5948.55.60903 Acute myocardial infarction64,92071,9098.45.20905 Pulmonary heart disease & diseases of pulmonary circulation7,72512,2549.27.50906 Conduction disorders and cardiac arrhythmias54,46353,8725.15.20907 Heart failure60,32165,51010.110.10908 Cerebrovascular diseases52,95453,04916.713.20909 Atherosclerosis7,1356,83111.910.80910 Varicose veins of lower extremities2,4041,0465.711.70911 Other diseases of the circulatory system49,29455,7329.18.71000 Diseases of the respiratory system2,57,5722,72,3156.67.41001 Acute upper respiratory infections and influenza17,87522,7042.74.61002 Pneumonia78,93867,9747.97.41003 Other acute lower respiratory infections20,21517,1193.73.71004 Chronic diseases of tonsils and adenoids12,2835,8581.21.11005 Other diseases of upper respiratory tract11,0388,1522.42.71006 Chronic obstructive pulmonary disease and bronchiectasis55,75789,8979.28.11007 Asthma31,01011,4433.52.91008 Other diseases of the respiratory system30,45649,1689.911.41101 Disorders of teeth and supporting structures6,7685,8262.21.81102 Other diseases of oral cavity, salivary glands and jaws2,7332,8933.74.51103 Diseases of oesophagus10,6817,8775.25.61104 Peptic ulcer11,1499,6927.37.31105 Dyspepsia and other diseases of stomach and duodenum13,6577,3784.96.41106 Diseases of appendix29,73738,5813.62.41107 Inguinal hernia20,70210,7142.53.21108 Other abdominal hernia17,44617,9854.34.51109 Crohn\'s disease and ulcerative colitis12,58610,0999.27.81111 Paralytic ileus and intestinal obstruction without hernia25,37430,1237.57.01112 Diverticular disease of intestine19,12718,3587.36.21113 Diseases of anus and rectum8,5129,2634.24.41114 Other diseases of intestine12,73114,5158.38.41115 Alcoholic liver disease4,7556,18511.912.51116 Other diseases of liver6,8029,91111.511.21117 Cholelithiasis49,08033,6063.74.01118 Other diseases of gall bladder and biliary tract10,08013,0675.76.01119 Diseases of pancreas16,03724,0218.36.21120 Other diseases of the digestive system18,33725,7817.36.91200 Diseases of the skin and subcutaneous tissue31,04333,6137.99.31201 Infections of the skin and subcutaneous tissue23,47826,6346.67.91202 Dermatitis, eczema and papulosquamous disorders1,6161,7445.45.71203 Other diseases of the skin and subcutaneous tissue5,9495,23513.717.21300 Diseases of the musculoskeletal system and connective tissue1,30,7201,87,4837.05.71301 Coxarthrosis \[arthrosis of hip\].36,682.3.61302 Gonarthrosis \[arthrosis of knee\].62,850.3.51303 Internal derangement of knee4,1231,0281.71.61305 Systemic connective tissue disorders3,6993,33712.210.71306 Deforming dorsopathies and spondylopathies7,87315,6258.88.41307 Intervertebral disc disorders15,72610,8465.35.41308 Dorsalgia7,2977,7766.37.61309 Soft tissue disorders13,98512,2524.29.41310 Other disorders of the musculoskeletal system and connective tissue23,48916,8059.011.71400 Diseases of the genitourinary system1,77,2741,64,4584.35.21401 Glomerular and renal tubulo-interstitial diseases16,73124,2095.24.91402 Renal failure11,72323,90512.910.01403 Urolithiasis25,43815,0872.72.41404 Other diseases of the urinary system30,80540,7095.47.61405 Hyperplasia of prostate15,51213,4953.52.51406 Other diseases of male genital organs5,4244,2073.24.51407 Disorders of breast10,0732,4591.51.71408 Inflammatory diseases of female pelvic organs6,3453,5893.53.81409 Menstrual, menopausal and other female genital conditions19,07213,0153.01.8Appendix Table 4Estimates of β~k~ parameters of **semi-logarithmic version** of eq. [(4)](#fd4){ref-type="disp-formula"}, Δln(Y~d~) = β~k~ (CUM_DRUG~d,2016-k~ - CUM_DRUG~d,2000-k~) + δ'+ ε~d~'Appendix Table 4rowlagEstimateStd. Err.t Valuep-valueNmean (regressor)β~k~ \* mean (regressor)10**−0.00560.003−2.040.044**1368.357−0.04721−0.00260.003−0.990.3241368.682−0.02232**−0.00370.002−1.480.142**1369.203−0.03443**−0.00480.002−2.030.044**1369.811−0.04754**−0.00550.002−2.620.010**13611.028−0.06165**−0.00540.002−2.660.009**13611.464−0.06276**−0.00470.002−2.320.022**13611.816−0.05587**−0.00510.002−2.660.009**13612.535−0.06498**−0.00520.002−2.790.006**13612.814−0.066109**−0.00450.002−2.650.009**13614.021−0.0641110**−0.00420.002−2.460.016**13614.097−0.0591211**−0.00470.002−2.830.005**13614.691−0.0691312**−0.00430.002−2.600.011**13614.678−0.0631413**−0.00520.002−3.230.002**13614.769−0.0761514**−0.00520.002−3.350.001**13614.923−0.0781615**−0.00490.002−3.140.002**13614.972−0.0741716**−0.00540.002−3.290.001**13614.877−0.0801817**−0.00590.002−3.650.000**13614.770−0.0881918**−0.00570.002−3.390.001**13614.121−0.0802019**−0.00550.002−3.260.001**13613.946−0.0762120**−0.00510.002−2.870.005**13613.276−0.068Appendix Fig. 1Age-standardized percentage reporting a diagnosis of diabetes, by sex, population aged 12 or older, canada, 2000/2001,2003,2005,2007, and 2008.1Appendix Fig. 1

Potential years of life lost (PYLL) is an estimate of the average years a person would have lived if he or she had not died prematurely.

[@bib31] argued that "many if not most innovations need to be embodied in new kinds of durable equipment before they can be made effective. Improvements in technology affect output only to the extent that they are carried into practice either by net capital formation or by the replacement of old-fashioned equipment by the latest models ..." [@bib15], p. 223) concluded that "'embodiment' is the main transmission mechanism of technological progress to economic growth."

R&D intensity is the ratio of R&D to sales.

A medicinal substance can be given more than one ATC code if it is available in two or more strengths or routes of administration with clearly different therapeutic uses ([@bib35].

The trend in one behavioural risk factor---obesity---may have *increased* the burden of disease. Between 2003 and 2014, the fraction of Canadian men whose reported height and weight classified them as obese increased from 16.0% to 21.8%; the fraction of Canadian women whose reported height and weight classified them as obese increased from 14.5% to 18.7% ([@bib33]).

Many drugs are used to treat multiple diseases: 50% of drugs are used to treat 2 or more diseases, 25% of drugs are used to treat 3 or more diseases, and 14% of drugs are used to treat 4 or more diseases.

To estimate YLDs for a particular cause in a particular time period, the number of incident cases in that period is multiplied by the average duration of the disease and a weight factor that reflects the severity of the disease on a scale from 0 (perfect health) to 1 (dead). The 'valuation' of time lived in non-fatal health states formalizes and quantifies the loss of health for different states of health as *disability weights*. In the standard DALYs reported by the original Global Burden of Disease study and in subsequent WHO updates, calculations of YLDs and YLLs used an additional 3% time discounting and non-uniform age weights that give less weight to years lost at young and older ages ([@bib24]). Using discounting and age weights, a death in infancy corresponds to 33 DALYs, and deaths at ages 5--20 years to around 36 DALYs.

In addition to estimating models based on the log-log specification (eq. [(1)](#fd1){ref-type="disp-formula"}), I will estimate models based on the log-linear specification ln(Y~ct~) = β~k~ CUM_DRUG~c,t-k~ + α~c~ + δ~t~ + ε~ct~.

The discovery of new ideas could increase economic output for two different reasons. First, output could simply be positively related to the *quantity* (and variety) of ideas ever discovered. Second, output could be positively related to the (mean or maximum) *quality* of ideas ever discovered, and new ideas may be better (of higher quality), on average, than old ideas.

Much of the rest came from the federal government (i.e. the NIH), and new drugs often build on upstream government research ([@bib30]). The [@bib25] says that it "has played a vital role in cancer drug discovery and development, and, today, that role continues."

The parameter δ′ in eq. [(4)](#fd4){ref-type="disp-formula"} is an estimate of the mean log change in disease burden in the absence of any drug launches between 2000 -- k and 2016 -k.

Percentage deviations of observations with low disease burden means exhibit much greater variance and volatility than percentage changes of observations with high average disease burden means.

The estimate of a 12--14 year lag from drug launch to peak drug utilization in Canada is 4 years longer than the average 8--10 year lag in 22 countries (Australia, Austria, Belgium, Brazil, Canada, Switzerland, Chile, Colombia, Germany, Ecuador, Spain, Finland, France, United Kingdom, Ireland, Italy, Japan, Mexico, Portugal, Singapore, Sweden, and the U.S.) estimated in [@bib23]. In that study, data on drug launch dates were obtained from a different data source: the IQVIA New Product Focus database.

[@bib13] argued that "innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production." [@bib4] stated simply that "new goods are at the heart of economic progress," and [@bib3] said that "much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models." As noted by [@bib18], in "the Spence--Dixit--Stiglitz tradition ... new goods \[are\] of higher quality than old goods."

The impact on mortality may depend on the *interaction* (quantity \* quality) of the two variables. The mortality impact will increase with respect to drug age (time since launch) if the rate of increase of quantity with respect to age is greater than the rate of decline of quality with respect to age; otherwise the mortality impact will decline.

These data may also be obtained from the [@bib12].

Theriaque provides data only on labeled indications; it does not provide data on off-label indications.

If all 6 cardiovascular diseases are removed from the sample, the point estimate of β~15~ is −0.209 and is still highly significant (t-value = 4.02; p-value = .0001).

This may be related to the rise in obesity described earlier.

Also, estimates of the semi-logarithmic functional form are more likely to be influenced by the disease classification/aggregation scheme than estimates of the log-log functional form.

As shown in Appendix [Table 1](#tbl1){ref-type="table"}, the magnitudes of YLL and YLD were almost identical in 2016. The age-standardized YLL rate declined by 25% between 2000 and 2016, but the age-standardized YLD rate increased by 1% between 2000 and 2016.

The YLD data we analyze are probably subject to much greater measurement error than the YLL data. In general, disability is more difficult to measure than death. Intensive searching of the Health Canada and Statistics Canada websites indicated that hardly any Canada-specific data on disability, by disease and year, exist. Therefore, the WHO YLD data may be largely imputed from other, non-Canadian sources. Better-quality disease-specific disability data are available for the U.S. and European countries. Two studies (e.g. [@bib22]) based on data from those regions have shown that new drugs have reduced disability.

As shown in Appendix [Table 3](#tbl3){ref-type="table"}, average length of stay for all medical conditions increased from 7.2 days in 2000 to 8.1 days in 2016.

The intercept (δ′) of that model is positive but not statistically significant (estimate = 0.046; t-value = 1.03; p-value = .305). The increase in obesity and diabetes prevalence might have caused the age-standardized DALY rate to increase.

This is about 1/3 (32%) of IQVIA\'s estimate of total pharmaceutical expenditure in 2016 (20.51 billion USD). IQVIA\'s estimate of total pharmaceutical expenditure is 17% lower than the estimate of 2016 expenditure on prescribed drugs reported in the Canadian Institute for Health Information\'s National Health Expenditure Database: 24.76 billion USD (= 32.15 billion CAD at a 0.77 USD/CAD exchange rate). But IQVIA\'s estimate is only 6% lower than the estimate of 2016 total pharmaceutical sales reported in the OECD Health Statistics Database: 21.82 billion USD (= 28.33 billion CAD at a 0.77 USD/CAD exchange rate).

A recently-published study ([@bib23]) of 66 diseases in 27 countries during the period 2000--2013, which employed a 3-way fixed-effects design that controlled for the average decline in the YLL rate in each country and from each disease, yielded a virtually identical cost-effectiveness estimate.

In the U.S. in 2014, rebates reduced total brand name drug cost by 17.5% (Centers for Medicare & Medicaid Services (2018)).

That study also demonstrated that pharmaceutical innovation has reduced work-loss and school-loss days.

Many drugs have multiple indications: 50% of drugs have 2 or more indications (causes of disease in the WHO Global Health Estimates disease classification), and 7% of drugs have 5 or more indications.

[^1]: 1\. Age-standardized rate based on population age distribution in 2000.
